Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study

Molecular Oncology

Volumn 8, Issue 5, 2014, Pages 874-883

  Kodahl, Annette R ^a,b   Lyng, Maria B ^b   Binder, Harald ^c   Cold, Søren ^a,b   Gravgaard, Karina ^b   Knoop, Ann S ^d   Ditzel, Henrik J ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Breast cancer; MiRNA; Serum markers

Indexed keywords

ESTROGEN RECEPTOR; MICRORNA; MICRORNA 107; MICRORNA 133A; MICRORNA 139 5P; MICRORNA 143; MICRORNA 145; MICRORNA 15A; MICRORNA 18A; MICRORNA 365; MICRORNA 425; TUMOR MARKER; UNCLASSIFIED DRUG; GENETIC MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; TUMOR VOLUME; CLINICAL ARTICLE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; LYMPH NODE; MENOPAUSE; BLOOD; BREAST; BREAST TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84903546990     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.03.002     Document Type: Article

References (55)

1. Andreasen D., Fog J.U., Biggs W., Salomon J., Dahslveen I.K., Baker A., Mouritzen P. Improved microRNA quantification in total RNA from clinical samples. Methods 2010, 50:S6-S9.
2. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., Mitchell P.S., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5003-5008.
3. Asaga S., Kuo C., Nguyen T., Terpenning M., Giuliano A.E., Hoon D.S. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 2011, 57:84-91.
4. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
5. Biagioni F., Bossel Ben-Moshe N., Fontemaggi G., Canu V., Mori F., Antoniani B., Di Benedetto A., et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol. Med. 2012, 4:1214-1229.
6. Binder H., Schumacher M. Adapting prediction error estimates for biased complexity selection in high-dimensional bootstrap samples. Stat. Appl. Genet. Mol. Biol. 2008, 7. Article12.
7. Blichert-Toft M., Christiansen P., Mouridsen H.T. Danish Breast Cancer Cooperative Group-DBCG: history, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol. 2008, 47:497-505.
8. Blondal T., Jensby Nielsen S., Baker A., Andreasen D., Mouritzen P., Wrang Teilum M., Dahlsveen I.K. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 2013, 59:S1-S6.
9. Carney P.A., Miglioretti D.L., Yankaskas B.C., Kerlikowske K., Rosenberg R., Rutter C.M., Geller B.M., et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann. Intern. Med. 2003, 138:168-175.
10. Chan M., Liaw C.S., Ji S.M., Tan H.H., Wong C.Y., Thike A.A., Tan P.H., et al. Identification of circulating microRNA signatures for breast cancer detection. Clin. Cancer Res. 2013, 19:4477-4487.
11. Chen P.S., Su J.L., Cha S.T., Tarn W.Y., Wang M.Y., Hsu H.C., Lin M.T., et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J. Clin. Invest. 2011, 121:3442-3455.
12. Chen W., Cai F., Zhang B., Barekati Z., Zhong X.Y. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 2013, 34:455-462.
13. Cheng C.W., Wang H.W., Chang C.W., Chu H.W., Chen C.Y., Yu J.C., Chao J.I., et al. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res. Treat. 2012, 134:1081-1093.
14. Cookson V.J., Bentley M.A., Hogan B.V., Horgan K., Hayward B.E., Hazelwood L.D., Hughes T.A. Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol. (Dordr.) 2012, 35:301-308.
15. Cuk K., Zucknick M., Heil J., Madhavan D., Schott S., Turchinovich A., Arlt D., et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer 2013, 132:1602-1612.
16. Di Leva G., Croce C.M. Roles of small RNAs in tumor formation. Trends Mol. Med. 2010, 16:257-267.
17. Eichelser C., Flesch-Janys D., Chang-Claude J., Pantel K., Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem. 2013, 59:1489-1496.
18. Espelund U., Cold S., Frystyk J., Orskov H., Flyvbjerg A. Elevated free IGF2 levels in localized early-stage breast cancer in women. Eur. J. Endocrinol. 2008, 159:595-601.
19. Godfrey A.C., Xu Z., Weinberg C.R., Getts R.C., Wade P.A., Deroo L.A., Sandler D.P., et al. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 2013, 15:R42.
20. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2010, 251:499-505.
21. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
22. Jensen S.G., Lamy P., Rasmussen M.H., Ostenfeld M.S., Dyrskjot L., Orntoft T.F., Andersen C.L. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011, 12:435.
23. Kirschner M.B., Kao S.C., Edelman J.J., Armstrong N.J., Vallely M.P., van Zandwijk N., Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 2011, 6:e24145.
24. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
25. Langagergaard V., Garne J.P., Vejborg I., Schwartz W., Bak M., Lernevall A., Mogensen N.B., et al. Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening. Clin. Epidemiol. 2013, 5:81-88.
26. Leidner R.S., Li L., Thompson C.L. Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One 2013, 8:e57841.
27. Li M., Marin-Muller C., Bharadwaj U., Chow K.H., Yao Q., Chen C. MicroRNAs: control and loss of control in human physiology and disease. World J. Surg. 2009, 33:667-684.
28. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
29. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
30. Maclellan S.A., Lawson J., Baik J., Guillaud M., Poh C.F., Garnis C. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med. 2012, 1:268-274.
31. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 2005, 97:1180-1184.
32. Mestdagh P., Van Vlierberghe P., De Weer A., Muth D., Westermann F., Speleman F., Vandesompele J. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009, 10:R64.
33. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
34. Ng E.K., Li R., Shin V.Y., Jin H.C., Leung C.P., Ma E.S., Pang R., et al. Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 2013, 8:e53141.
35. Nylander E., Ebrahimi M., Wahlin Y.B., Boldrup L., Nylander K. Changes in miRNA expression in sera and correlation to duration of disease in patients with multifocal mucosal lichen planus. J. Oral Pathol. Med. 2012, 41:86-89.
36. Pisano E.D., Hendrick R.E., Yaffe M.J., Baum J.K., Acharyya S., Cormack J.B., Hanna L.A., et al. Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 2008, 246:376-383.
37. Romero-Cordoba S., Rodriguez-Cuevas S., Rebollar-Vega R., Quintanar-Jurado V., Maffuz-Aziz A., Jimenez-Sanchez G., Bautista-Pina V., et al. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One 2012, 7:e31904.
38. Roth C., Rack B., Muller V., Janni W., Pantel K., Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010, 12:R90.
39. Sauerbrei W., Boulesteix A.-L., Binder H. Stability investigations of multivariable regression models derived from low- and high-dimensional data. J. Biopharm. Stat. 2011, 21:1206-1231.
40. Schrauder M.G., Strick R., Schulz-Wendtland R., Strissel P.L., Kahmann L., Loehberg C.R., Lux M.P., et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 2012, 7:e29770.
41. Taplin S., Abraham L., Barlow W.E., Fenton J.J., Berns E.A., Carney P.A., Cutter G.R., et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J. Natl. Cancer Inst. 2008, 100:876-887.
42. Tutz G., Binder H. Boosting ridge regression. Comput. Stat. Data Anal. 2007, 51:6044-6059.
43. van der Meij E.H., Mast H., van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol. 2007, 43:742-748.
44. van Schooneveld E., Wouters M.C., Van der Auwera I., Peeters D.J., Wildiers H., Van Dam P.A., Vergote I., et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012, 14:R34.
45. Viale G., Regan M.M., Maiorano E., Mastropasqua M.G., Dell'Orto P., Rasmussen B.B., Raffoul J., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol. 2007, 25:3846-3852.
46. Wang F., Zheng Z., Guo J., Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 2010, 119:586-593.
47. Wang K., Yuan Y., Cho J.H., McClarty S., Baxter D., Galas D.J. Comparing the MicroRNA spectrum between serum and plasma. PLoS One 2012, 7:e41561.
48. Weiland M., Gao X.H., Zhou L., Mi Q.S. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012, 9:850-859.
49. Wijnhoven B.P., Michael M.Z., Watson D.I. MicroRNAs and cancer. Br. J. Surg. 2007, 94:23-30.
50. Wu Q., Lu Z., Li H., Lu J., Guo L., Ge Q. Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol. 2011, 2011:597145.
51. Wu Q., Wang C., Lu Z., Guo L., Ge Q. Analysis of serum genome-wide microRNAs for breast cancer detection. Clin. Chim. Acta 2012, 413:1058-1065.
52. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., Zeng Y.X., et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
53. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Development. Biol. 2007, 302:1-12.
54. Zhao F.L., Hu G.D., Wang X.F., Zhang X.H., Zhang Y.K., Yu Z.S. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J. Int. Med. Res. 2012, 40:859-866.
55. Zhao H., Shen J., Medico L., Wang D., Ambrosone C.B., Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010, 5:e13735. Web references. http://www.mirbase.org/.